Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

globenewswire.com
MRK Mentioned for its drug KEYTRUDA in the context of peripheral T-cell lymphoma treatment. The article discusses the overall market expansion and the role of emerging therapies, including KEYTRUDA, in driving this growth. The sentiment is neutral as it's part of a list of drugs and not highlighted for specific performance. IPHA Innate Pharma's Lacutamab is mentioned as a first-in-class antibody targeting KIR3DL2 for CTCL and PTCL. Data from a Phase II PTCL study is expected by the end of 2026, suggesting ongoing development but without explicit positive or negative outcomes yet. VERU Verastem, Inc. is listed as a company developing PTCL drugs in the pipeline. No specific drug or trial details are provided, making the sentiment neutral and the strength weak based solely on its inclusion in a list. KURA Kura Oncology, Inc. is listed as a company developing PTCL drugs in the pipeline. No specific drug or trial details are provided, making the sentiment neutral and the strength weak based solely on its inclusion in a list. INCY Incyte Corporation is listed as a company developing PTCL drugs in the pipeline. No specific drug or trial details are provided, making the sentiment neutral and the strength weak based solely on its inclusion in a list. AMGN Amgen is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Amgen's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. PFE Pfizer is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Pfizer's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. GILD Gilead Sciences is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Gilead's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. REGN Regeneron Pharmaceuticals is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Regeneron's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. AZN AstraZeneca is mentioned for its drug Golidocitinib (AZD4205/DZD4205) in development for PTCL. The article lists it among emerging therapies, indicating potential but without specific trial results or market performance data provided. CRSP CRISPR Therapeutics is listed as a company developing Follicular Lymphoma drugs. The article focuses on PTCL, and CRISPR's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. BIIB Biogen is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Biogen's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. NTRA Nektar Therapeutics is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Nektar's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. ALLO Allogene Therapeutics is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Allogene's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. KYMR Kymera Therapeutics is listed as a company developing PTCL drugs in the pipeline. No specific drug or trial details are provided, making the sentiment neutral and the strength weak based solely on its inclusion in a list. ADCT Adicet Bio is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Adicet Bio's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. IMUX ImmunoVaccine Technologies is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and ImmunoVaccine's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. CELC Cellectar Biosciences is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Cellectar's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. ONON ONO Pharmaceutical is listed as a company developing Cutaneous T-cell Lymphoma drugs. The article focuses on PTCL, and ONO's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. ABBV AbbVie is mentioned as a company involved in the Non-Hodgkin's Lymphoma market. The article focuses on PTCL, and AbbVie's mention is in a broader context of related lymphomas, making the sentiment neutral and strength moderate. TDOC Takeda is mentioned as a company involved in the Non-Hodgkin's Lymphoma market. The article focuses on PTCL, and Takeda's mention is in a broader context of related lymphomas, making the sentiment neutral and strength moderate. BMY Bristol Myers Squibb is mentioned as a company involved in the Non-Hodgkin's Lymphoma, Cutaneous T-cell Lymphoma, and Follicular Lymphoma markets. The article focuses on PTCL, and BMS's mention is in a broader context of related lymphomas, making the sentiment neutral and strength moderate. IMVT ImmunoVaccine Technologies is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and ImmunoVaccine's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. GNTX Genentech (a Member of Roche) is mentioned as a company involved in the Non-Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma markets. The article focuses on PTCL, and Genentech's mention is in a broader context of related lymphomas, making the sentiment neutral and strength moderate. IMPP ImmPACT Bio is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and ImmPACT Bio's mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus. AUTL Autolus Therapeutics is listed as a company developing Diffuse Large B-cell Lymphoma drugs. The article focuses on PTCL, and Autolus Therapeutics' mention is in a related but distinct market context, making the sentiment neutral and strength weak for this specific article's focus.

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight New York, USA, April 27, 2026 (GLOBE NEWSWIRE) -- Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

The peripheral T-cell lymphoma treatment market is witnessing steady growth, primarily driven by the increasing incidence, leading to an increased patient population, which fuels the ongoing treatment demand. Additionally, the launch of emerging therapies such as Duvelisib (COPIKTRA) (Secura Bio), Lacutamab (IPH4102) (Innate Pharma), Linperlisib (YY-20394/linprixetine) (Shanghai YingLi Pharmaceutical), KEYTRUDA (Merck), OPDIVO (BMS), Golidocitinib (AZD4205/DZD4205) (Dizal Pharmaceuticals), and others will further propel the market growth forward in the coming years.

Recently published PTCL Market Insights report includes a comprehensive understanding of current treatment practices, peripheral T-cell lymphoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Peripheral T-Cell Lymphoma Market Summary

Discover which region dominates the PTCL market @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

Key Factors Driving the Growth of the Peripheral T-Cell Lymphoma Market

Sadaf Javed, oncology expert at DelveInsight, said that with multiple late-stage and mid-stage assets progressing amid a small, fragmented market, future success will favor therapies that demonstrate clear superiority over existing agents, biomarker-aligned positioning, and scalable commercialization strategies from financially resilient players.

Peripheral T-Cell Lymphoma Market Analysis

Learn more about the upcoming approvals in the PTCL market @ Peripheral T-Cell Lymphoma Treatment Market

Peripheral T-Cell Lymphoma Competitive Landscape

Some of the PTCL drugs under development include Duvelisib (COPIKTRA) (Secura Bio), Lacutamab (IPH4102) (Innate Pharma), Linperlisib (YY-20394/linprixetine) (Shanghai YingLi Pharmaceutical), KEYTRUDA (Merck), OPDIVO (BMS), Golidocitinib (AZD4205/DZD4205) (Dizal Pharmaceuticals), and others.

Secura Bio’s Duvelisib (COPIKTRA) is an orally administered inhibitor of phosphoinositide 3-kinase (PI3K). Activation of the PI3K pathway is associated with the growth of malignant cells and is believed to contribute to the development and persistence of a supportive tumor microenvironment. In December 2025, Secura Bio reported that its Phase III TERZO trial is progressing as planned, with an interim data readout expected in early 2027 based on current enrollment; the study was initiated earlier in the year, with the first patient dosed in June.

Innate Pharma’s Lacutamab is a first-in-class, humanized antibody targeting KIR3DL2 that induces cytotoxicity. It is currently under evaluation in an open-label, multicohort Phase II study in CTCL, as well as a separate Phase II trial in PTCL. In December 2025, Innate Pharma indicated that data from the Phase II PTCL study are expected by the end of 2026.

Shanghai YingLi Pharmaceutical’s Linperlisib is a highly selective and potent PI3Kδ inhibitor with a favorable safety profile. It has demonstrated encouraging anti-tumor activity along with promising pharmacokinetic and pharmaceutical characteristics as a once-daily oral therapy in clinical development. The drug has been evaluated across three clinical trials in relapsed/refractory PTCL in China, the United States, and Europe, involving more than 165 treated patients.

Dizal Pharmaceuticals’ Golidocitinib is currently the first and only selective Janus kinase 1 (JAK1) inhibitor under investigation for the treatment of relapsed/refractory PTCL. Phase I results (JACKPOT8 Part A) have been published in Annals of Oncology, while data from the global pivotal trial (JACKPOT Part B) were published in The Lancet Oncology.

The anticipated launch of these emerging peripheral T-cell lymphoma therapies are poised to transform the peripheral T-cell lymphoma market landscape in the coming years. As these cutting-edge peripheral T-cell lymphoma therapies continue to mature and gain regulatory approval, they are expected to reshape the peripheral T-cell lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about top companies developing PTCL drugs, visit @ Peripheral T-Cell Lymphoma Medication

Recent Developments in the Peripheral T-Cell Lymphoma Market

What is Peripheral T-Cell Lymphoma?

Peripheral T-cell lymphoma (PTCL) is a rare and aggressive group of cancers that arises from mature T lymphocytes, a type of white blood cell essential for immune function. It falls under the broader category of non-Hodgkin lymphoma and encompasses several biologically diverse subtypes, such as PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL). PTCL typically presents with symptoms like enlarged lymph nodes, fever, weight loss, and night sweats, often indicating advanced disease at diagnosis. Compared to B-cell lymphomas, PTCL generally has a poorer prognosis and limited treatment options, with standard therapies including combination chemotherapy, targeted agents, and, in some cases, stem cell transplantation.

Peripheral T-Cell Lymphoma Epidemiology Segmentation

The peripheral T-cell lymphoma patient pool analysis section provides insights into the historical and current peripheral T-cell lymphoma patient pool and forecasted trends for the leading markets. In Japan, the increase in PTCL incidence is driven by the Endemic HTLV-1 infection, particularly in southwestern Japan, which directly increases the incidence of adult T-cell leukemia/lymphoma (ATL), a major PTCL subtype, contributing to higher overall PTCL rates.

The peripheral T-cell lymphoma market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand unmet needs in PTCL therapy @ Peripheral T-Cell Lymphoma Treatment Options

Scope of the Peripheral T-Cell Lymphoma Market Report

Discover more about PTCL pipeline drugs 2026 @ Peripheral T-Cell Lymphoma Clinical Trials

Table of Contents

Related Reports

Peripheral T-Cell Lymphoma Clinical Trial Analysis Pipeline

Peripheral T-Cell Lymphoma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Peripheral T-Cell Lymphoma companies, including Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co., Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.

Non-Hodgkin’s Lymphoma Market

Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-Hodgkin’s lymphoma companies, including Soligenix, Innate Pharma, Nurix Therapeutics, AstraZeneca, Merck, Prescient Therapeutics, Kite Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member of Roche), Bristol Myers Squibb, and others.

Cutaneous T-cell Lymphoma Market

Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, and others.

Follicular Lymphoma Market

Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key follicular lymphoma Market companies, including Merck Sharp and Dohme, AstraZeneca, CRISPR Therapeutics, BeiGene, Nektar Therapeutics, NovalGen, Carna Biosciences, Allogene Therapeutics, Xynomic Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, among others.

Diffuse Large B-cell Lymphoma Market

Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies, including Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.